Project Description

PRIN 2022

Harnessing the genetics of gastrointestinal endophenotypes as a strategy to improve prevention, treatment and therapeutic precision in irritable bowel syndrome (IBS)

IBS (Irritable Bowel Syndrome) affects 10-15% of the population, causing recurrent abdominal pain, bloating, constipation, and diarrhea. These symptoms can worsen due to stress, diet, or hormonal changes. The exact causes of IBS remain unknown, and current treatments only target symptoms with limited effectiveness.

This research aims to uncover the genetic mechanisms behind IBS by studying measurable traits (endophenotypes) related to gut motility. Using stool consistency and frequency data from large biobanks (UK Biobank and Lifelines), researchers will conduct genome-wide association studies (GWAS) to identify relevant genetic regions.

The ultimate goal is to improve IBS risk prediction and develop new targeted treatments by identifying druggable pathways. Potential therapeutic strategies include microbiome modulation, hormonal treatments, or personalized medicine approaches, paving the way for more effective IBS prevention and management.

Funding sources:

The project is funded by Next-Generation EU, Mission 4 Component 1 (PRIN2022 2022PMZKEC CUP MASTER E53D23004910008 CUP B53D23008300006)

Research Teams:

The project is coordinated by Prof. Mauro D’amato from Libera Università Mediterranea di Bari. His team works in collaboration with the IRGB team, led by Dr. Serena Sanna.